|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
|
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 17, 2025
Vivani Medical, Inc.
(Exact
name of Registrant as Specified in Its Charter)
| Delaware |
|
001-36747 |
|
02-0692322 |
|
(State
or Other Jurisdiction of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1350 S. Loop Road
Alameda, California 94502
(Address of principal executive offices, including zip code)
(415) 506-8462
(Telephone number, including area code, of agent for service)
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
VANI |
|
The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure
The Company from time to
time presents and/or distributes to the investment community at various
industry and other conferences slide presentations to provide updates and
summaries of its business. These slides are attached to this Current Report on
Form 8-K as Exhibit 99.1 and are incorporated by reference herein. The Company
is also posting to the “Investors” portion of its website a copy of its current
corporate slide presentation. The slides speak as of the date of this Current
Report on Form 8-K. While the Company may elect to update the slides in the
future or reflect events and circumstances occurring or existing after the date
of this Current Report on Form 8-K, the Company specifically disclaims any
obligation to do so.
The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
VIVANI MEDICAL, INC.
|
|
|
|
|
|
Date: June 17, 2025
|
By:
|
/s/ Donald Dwyer
|
|
|
Name:
|
Donald Dwyer
|
|
|
Title:
|
Chief Business Officer
|
